Matthew Vincent Dolan's Insider Trades & SAST Disclosures
Matthew Vincent Dolan's most recent trade in Dexcom Inc was a trade of 3,048 Common Stock done . Disclosure was reported to the exchange on Jan. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew Vincent Dolan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dexcom Inc | Matthew Vincent Dolan | EVP, Strategy & Corporate Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 3,048 | 43,227 (0%) | 0% | 0 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP, Strategy & Corporate Dev | Sale of securities on an exchange or to another person at price $ 86.91 per share. | 28 Jan 2025 | 1,183 | 42,044 (0%) | 0% | 86.9 | 102,820 | Common Stock |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy and Corporate Dev | 15 May 2024 | 2,423 | 40,075 (0%) | 0% | 126.6 | 306,703 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy and Corporate Dev | 15 Apr 2024 | 1,990 | 42,377 (0%) | 0% | 137.8 | 274,242 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy & Corp Dev | 15 Mar 2024 | 1,886 | 46,684 (0%) | 0% | 129.2 | 243,641 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy & Corp Dev | 15 Mar 2024 | 1,314 | 45,370 (0%) | 0% | 130.8 | 171,832 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy & Corp Dev | 15 Mar 2024 | 1,003 | 44,367 (0%) | 0% | 131.4 | 131,785 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy and Corporate | 12 Mar 2024 | 6,710 | 48,570 (0%) | 0% | 134.4 | 901,896 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | EVP Strategy and Corporate | 08 Mar 2024 | 21,711 | 55,280 (0%) | 0% | 0 | Common Stock | ||
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 16 Mar 2023 | 2,303 | 33,569 (0%) | 0% | 115 | 264,845 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 10 Mar 2023 | 6,229 | 35,872 (0%) | 0% | 106.3 | 661,956 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 10 Mar 2023 | 2,397 | 42,888 (0%) | 0% | 111.4 | 267,023 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 10 Mar 2023 | 1,650 | 45,285 (0%) | 0% | 111.4 | 183,808 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 10 Mar 2023 | 1,370 | 46,935 (0%) | 0% | 111.4 | 152,617 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 10 Mar 2023 | 787 | 42,101 (0%) | 0% | 111.4 | 87,671 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 08 Mar 2023 | 21,769 | 48,305 (0%) | 0% | 0.0 | 22 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 06 Mar 2023 | 226 | 26,536 (0%) | 0% | 114.4 | 25,854 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Strategy-Develop | 01 Sep 2022 | 5 | 26,536 (0%) | 0% | 81.6 | 408 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 15 Mar 2022 | 1,016 | 7,804 (0%) | 0% | 412.4 | 419,009 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 15 Mar 2022 | 686 | 7,118 (0%) | 0% | 425 | 291,550 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 15 Mar 2022 | 484 | 6,634 (0%) | 0% | 450 | 217,800 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 08 Mar 2022 | 2,889 | 10,435 (0%) | 0% | 0.0 | 3 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 08 Mar 2022 | 541 | 8,820 (0%) | 0% | 406.1 | 219,677 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 08 Mar 2022 | 489 | 9,361 (0%) | 0% | 406.1 | 198,562 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 08 Mar 2022 | 393 | 10,042 (0%) | 0% | 406.1 | 159,580 | Common Stock | |
| Dexcom Inc | Matthew Vincent Dolan | SVP Corporate Development | 08 Mar 2022 | 192 | 9,850 (0%) | 0% | 406.1 | 77,963 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges